Emerging Markets
Support performance, reliability, and regulatory readiness for innovative diagnostics
Innovation to Accelerate the Future of Diagnostics
Rapid, accessible diagnostics are transforming healthcare by enabling detection, personalized treatment decisions, and expanded access to care. MRIGlobal partners with government and industry to support development of next-generation solutions. By integrating expertise in in vitro diagnostics, clinical testing, analytical validation, and regulatory science with emerging approaches—including agnostic pathogen detection, New Approach Methodologies (NAMs), advanced bioinformatics, and AI-enabled technologies—we help organizations translate innovation into robust, clinically meaningful products that address evolving healthcare and infectious disease challenges.
Advancing Accessible Diagnostic Innovation
Agnostic Pathogen Detection
Identify known and novel biological threats, without prior pathogen knowledge, using next-gen diagnostic platforms.
Human-Relevant New Approach Methods
Complex in vitro models, including microphysiological systems (MPS) and advanced 3D tissue cultures can accelerate therapeutic development, toxicity evaluation, and disease research beyond traditional animal testing.
Accelerating Agent Identification
Leverage unique computational and bioinformatic approaches to identify newly emerging, engineered, or synthetic agents to allow for rapid decision-making and responses.
Advancing Clinical Diagnostic Innovation
Advance clinical diagnostics through CAP/CLIA testing, assay development, and innovative solutions for emerging healthcare needs.
AI-Enabled Diagnostic Evaluation
Assess diagnostics that utilize emerging AI technologies to ensure accuracy, consistency, and clinical utility.
